BioNTech SE (BNTX) Reports Q1 Loss of EUR0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
May 12, 2020 8:05 AM EDTGlobal Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection in dose escalation phase in Europe and the U.S.; first cohorts dosed in both regionsBNT122 Phase 1/2 trial update expected at AACR Virtual Annual Meeting II in JuneEnded 1Q 2020 with cash equivalents of $495Â million (452Â million) with additional $236Â million (217Â million) in equity investments and non-dilutive upfront payments due in 2Q 2020 from Pfizer and Fosun PharmaConference call and webcast scheduled for May 12, 2020 at 08:00... More
